iX Biopharma, whose stock has shot up 157% year-to-date (to 35 cents), has announced a strategic internal restructuring to consolidate its consumer-facing assets under a new subsidiary, Ligo Pharma.

This entity will spearhead the company's entry into the US health market, commercialising its WaferiX sublingual technology through compounding and telehealth channels.

(Compounding is custom-preparing or mixing medications — instead of selling mass-produced, factory-made drugs that require full FDA approval.)

Furthermore, iX is negotiating a JV with Orion Specialty Labs and GLD Partners to integrate American pharmacy operations into this new structure.

https://www.nextinsight.net/story-archive-mainmenu-60/949-2026/16723-unlocking-value-ix-biopharma-creates-standalone-us-business-with-potential-spin-off-or-listing